DJIA 17,804.80 26.65 0.15%
NASDAQ 4,765.38 16.98 0.36%
S&P 500 2,070.65 9.42 0.46%
market minute promo


20.97 0.09 (0.41%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

TKPYY $20.97 0.41%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $20.94
Previous Close $20.88
Daily Range $20.88 - $21.00
52-Week Range $20.36 - $24.54
Market Cap $33.1B
P/E Ratio 0.00
Dividend (Yield) $0.00 (3.2%)
Volume 76,178
Average Daily Volume 54,280
Current FY EPS $0.55





News & Commentary

Is Sunesis Pharmaceuticals Poised for a Breakout?

The little-known biopharma Sunesis Pharmaceuticals is on the cusp of unblinding late-stage trial data for its flagship oncology drug vosaroxin. Leading into this seminal event, management sounds fairly confident of a positive result, but the market clearly has its doubts. Why?

Today’s Top Biotech Stories: Takeda, Eli Lilly, Immunomedics, and Pharmacyclics

Takeda, Eli Lilly, Immunomedics, and Pharmacyclics could loom large in health care headlines this Tuesday morning.

Orexigen Therapeutics Reduces Q4 Loss by 34%

Lower research and development expenses help lower Orexigen's quarterly loss.

Have Anti-Obesity Drug Prospects Finally Gone Belly-Up?

A number of factors are holding back obesity therapies, but this one glimmer of light has the potential to change that perception.

JPMorgan Healthcare Conference Highlights: Arena Pharmaceuticals, Inc.

Arena Pharmaceuticals takes the stage to highlight Belviq, other lorcaserin indications, and its remaining pipeline. Do investors have a reason to be excited?

JPMorgan Healthcare Conference Highlights: Pharmacyclics, Inc.

The JPMorgan Healthcare Conference kicks off and Pharmacyclics dishes new pricing and duration data on key drug Imbruvica.

Why Sucampo Pharmaceuticals, Inc. Shares Popped

Sucampo's 8-K filing with the SEC delivers a nice surprise to shareholders.

10 Countries With the Longest Life Expectancy

These are the 10 countries with the longest life expectancy. See what factors have allowed their citizens to live longer as well as how you might be able to benefit from their longevity.

Another High-Profile Diabetes Candidate Goes Down

With Takeda's recent setback, Big Pharma's diabetes cupboard is looking very bare.

Vedolizumab Gets High Marks for Treatment of Ulcerative Colitis, Less Effective on Crohn’s Disease

An FDA panel gives the green light on the use of vedolizumab to treat patients with ulcerative colitis and Crohn’s disease who failed other treatments.

See More TKPYY News...